(Q44295042)

English

Phase II study of continuous infusion recombinant gamma interferon in renal carcinoma. A Southwest Oncology Group study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Phase II study of continuous infusion recombinant gamma interferon in renal carcinoma. A Southwest Oncology Group study (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

author name string

J P Kuebler

1

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

P J Goodman

2

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

T D Brown

3

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

E D Crawford

4

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

C L Reitz

5

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

W A Knight

6

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

J A Kish

7

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

publication date

1 August 1990

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

307-309

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

https://scigraph.springernature.com/pub.10.1007/bf00171843

0 references

Phase II study of recombinant human interferon gamma (S-6810) on renal cell carcinoma. Summary of two collaborative studies. Recombinant Human Interferon Gamma (S-6810) Research Group on Renal Cell Carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/2125585

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/2125585

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I/II study of recombinant interferon gamma in advanced renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/2125585

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of biological response modifiers in metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/2125585

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immune interferon activates cells more slowly than does virus-induced interferon

1 reference

https://pubmed.ncbi.nlm.nih.gov/2125585

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I clinical trial of recombinant DNA gamma interferon

1 reference

https://pubmed.ncbi.nlm.nih.gov/2125585

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF00171843

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44295042&oldid=2109231288"